1 July 2026
Research grade manufacturing continues to generate revenue
Our GLP research grade facility continues to supply custom oligonucleotides to research, diagnostic and early development customers.
Investors Centre
An integrated life sciences company, built for scale.
Information for investors in Syngenis, an integrated life sciences company operating one platform across six connected pillars.
Investors Centre
Company information, governance and announcements.
Syngenis Labs Ltd is an integrated life sciences company building sovereign RNA and DNA discovery, manufacturing and clinical capability in Australia. This centre brings together company information, corporate governance documents and announcements for interested parties.
6
Connected pillars
1
Australia's only commercial RNA facility
43.5c
Per eligible R&D dollar
AU
Onshore, sovereign capability
Why Syngenis
Why Syngenis.
An integrated platform across six pillars, Australia's only commercial RNA manufacturing facility, revenue generating research grade manufacturing today, a world class scientific and advisory bench, and a sovereign, on home soil model. This overview is provided for information only.
One integrated platform
Six connected pillars on a single engine, so value compounds across the whole business.
Sovereign capability
Australia's only commercial RNA facility, onshore, with a world leading R&D incentive.
Revenue generating today
Research grade manufacturing is operational and generating revenue now, with GMP in build.
World class bench
A scientific and advisory bench that includes the inventor of the chemistry behind the field.
Corporate governance
Corporate governance.
Our governance documents are available to download directly.
Company ConstitutionDownload a copyBoard CharterDownload a copyAudit and Risk Committee CharterDownload a copyCode of ConductDownload a copyContinuous Disclosure PolicyDownload a copySecurities Trading PolicyDownload a copy
Sample documents. Final governance PDFs will be linked here for direct download.
Announcements
Announcements and updates.
15 May 2026
First AI discovered candidate enters laboratory validation
The first candidate designed end to end by Syngenis One has completed the discovery to laboratory workflow and entered validation.
10 March 2026
GMP, human grade facility in build
Construction continues on our GMP, human grade DNA and RNA manufacturing facility, targeted for 2027.
Sample announcements. The public Investors Centre is kept free of confidential capital raise material; any offer documents are handled through the proper private, compliant channel.
Work with us
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.
One Platform. Six Connected Pillars.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.